John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Systemic therapies of first and second lines fo hepatocellular carcinoma Volume 27, supplement 1, Mai 2020

Author
1 Hospices Civils de Lyon, Hôpital de la Croix Rousse, Unité d’Hépatologie et Gastroentérologie, 103, grande rue de la Croix Rousse, 69004 Lyon
2 Centre de Recherche en Cancérologie de Lyon, INSERM U1052, Lyon
3 Université Claude Bernard Lyon 1, Lyon
* Correspondance

Advanced hepatocellular carcinoma is prone to systemic therapies that have been tyrosine kinase inhibitors since 2007, mainly tumorostatic with poor tolerability. The arising of immuno-oncology has been disappointing in montherapy, but combined to regulators of the tumoral micro-environment, has been successful with striking improvement of efficacy and quality of life of patients. These date are completely modifying the paradigm of HCC therapeutic strategies.